Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

Spots can also look very different depending on your skin tone. Some pink, red, or brown spots are more obvious on fair to ...

Turmeric and curcumin are among the most powerful natural anti-inflammatory agents, offering benefits for joint health, brain ...

Psoriasis frequently appears on the arms, often on your elbow. Several types of psoriasis may affect your arms, but plaque psoriasis is the most common. The earliest sign may be a small bump, but the ...

Armpit rashes often develop due to allergic reactions, infections, and chronic conditions. Rashes are common under the arms because the skinfold creates a warm, moist environment. Additionally, the ...

Some evidence suggests a higher risk of liver disease with psoriasis. Certain psoriasis treatments can cause liver toxicity, but the two conditions also share common risk factors, which may ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials. The Protagonist Therapeutics-partnered IL-23 ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline results ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis. Johnson ...